Skip to main content

Table 1 Clinical characteristics of patients with de novo metastatic NPC (n = 502)

From: Identifying optimal candidates for local treatment of the primary tumor among patients with de novo metastatic nasopharyngeal carcinoma: a retrospective cohort study based on Epstein–Barr virus DNA level and tumor response to palliative chemotherapy

  EBV DNA levels after PCT Tumor response to PCT
Characteristic Undetectable Detectable P-value CR/PR SD/PD P-value
Total 249 253   317 185  
Gender
 Male 204 (81.9%) 213 (84.2%) 0.552 260 (82.0%) 157 (84.9%) 0.460
 Female 45 (18.1%) 40 (15.8%)   57 (18.0%) 28 (15.1%)  
Age (years)
  ≤ 47 133 (53.4%) 128 (50.6%) 0.533 165 (52.1%) 96 (51.9%) 1.000
  > 47 116 (46.6%) 125 (49.4%)   152 (47.9%) 89 (48.1%)  
T stage
 T1 10 (4.0%) 11 (4.3%) 1.000 10 (3.2%) 11 (5.9%) 0.467
 T2 31 (12.4%) 32 (12.6%)   39 (12.3%) 24 (13.0%)  
 T3 123 (49.4%) 125 (49.4%)   161 (50.8%) 87 (47.0%)  
 T4 85 (34.1%) 85 (33.6%)   107 (33.8%) 63 (34.1%)  
N stage
 N0 13 (5.2%) 3 (1.2%) 0.002 11 (3.5%) 5 (2.7%) 0.790
 N1 53 (21.3%) 36 (14.2%)   55 (17.4%) 34 (18.4%)  
 N2 101 (40.6%) 101 (39.9%)   132 (41.6%) 70 (37.8%)  
 N3 82 (32.9%) 113 (44.7%)   119 (37.5%) 76 (41.1%)  
Metastatic sites
 Bone 130 (52.2%) 96 (37.9%) < 0.001 157 (49.5%) 69 (37.3%) < 0.001
 Lung 44 (17.7%) 20 (7.9%)   48 (15.1%) 16 (8.6%)  
 Liver 20 (8.0%) 29 (11.5%)   28 (8.8%) 21 (11.4%)  
 Distant nodal 23 (9.2%) 12 (4.7%)   27 (8.5%) 8 (4.3%)  
 Multiple sites 32 (12.9%) 96 (37.9%)   57 (18.0%) 71 (38.4%)  
PCT regimens
 TPF 77 (30.9%) 53 (20.9%) 0.081 85 (26.8%) 45 (24.3%) 0.639
 TP 59 (23.7%) 62 (24.5%)   81 (25.6%) 40 (21.6%)  
 PF 63 (25.3%) 68 (26.9%)   78 (24.6%) 53 (28.6%)  
 GP 10 (4.0%) 17 (6.7%)   18 (5.7%) 9 (4.9%)  
 Others 40 (16.1%) 53 (20.9%)   55 (17.4%) 38 (20.5%)  
LRRT
 Yes 194 (77.9%) 121 (47.8%) < 0.001 219 (69.1%) 96 (51.9%) < 0.002
 No 55 (22.1%) 132 (52.2%)   98 (30.9%) 89 (48.1%)  
  1. Abbreviations: EBV Epstein-Barr virus, PCT palliative chemotherapy, CR complete response, PR partial response, PD disease progression, SD stable disease, TPF cisplatin plus docetaxel plus 5-fluorouracil, TP cisplatin plus docetaxel, PF cisplatin plus 5-fluorouracil, GP cisplatin plus gemcitabine, LRRT locoregional radiotherapy
  2. Undetectable/detectable EBV-DNA levels after PCT is based on a cutoff value of 0 copies per milliliter
  3. P-value was calculated with the Pearson χ2 test
\